AIM ImmunoTech Inc. (NYSE:AIM - Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as $14.93 and last traded at $9.90, with a volume of 41869 shares traded. The stock had previously closed at $9.50.
AIM ImmunoTech Trading Up 10.0%
The company has a market cap of $755.43 million, a price-to-earnings ratio of -22.86 and a beta of 0.76. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75. The business's 50-day simple moving average is $0.09 and its 200-day simple moving average is $0.14.
About AIM ImmunoTech
(
Get Free Report)
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AIM ImmunoTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AIM ImmunoTech wasn't on the list.
While AIM ImmunoTech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
